Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial

The Lancet Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles